menu
    • menu
    [{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Tree MATA MPL","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Grass MATA MPL","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-Based Peanut Allergy Vaccine","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergy Therapeutics \/ Allergy Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ Allergy Therapeutic"}]

    Find Clinical Drug Pipeline Developments & Deals by Allergy Therapeutics

    Menu

    Allergy Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP-Based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP-Based Peanut Allergy Vaccine

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Announces Start of Innovative Exploratory Field Study to Evaluate Efficacy and Safety of ...

                            Details : Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.

                            Brand Name : Grass MATA MPL

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            October 26, 2020

                            Lead Product(s) : Grass MATA MPL

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tree MATA MPL

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Announces Invalidation of the Birch MATA MPL Phase III Primary Endpoint Results

                            Details : Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergen...

                            Brand Name : Tree MATA MPL

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 09, 2020

                            Lead Product(s) : Tree MATA MPL

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth